French said Pulmonx expects contributions from improving sales-representative productivity, new treating centers and deeper utilization at established programs as it works toward stronger growth. Pulmonx plans to focus during the rest of 2026 on restarting commercial activity and re-engaging accounts in China. He said the company expects to remain “comfortably at or above 75%” gross margin over time, even after shipments to China resume. Sung said Pulmonx expects to use roughly $23 million of cash in 2026, nearly 30% less than its 2025 cash burn. About Pulmonx (NASDAQ:LUNG)Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema.